Selank for anxiety and GLP-1 support: what the science says

What did @kaitlynnglpmama actually say?

She said selank "quieted everything down," helped her sleep, and left her feeling "so calm" the next morning, describing it as what "normal people feel like." She plans a five-days-on, two-days-off cycle and calls it a new best friend after a single weekend. To her credit, she frames this as personal research rather than a prescription, repeatedly saying "research with it" rather than "take it." That framing matters, and it is the most responsible thing she does in this video.

Her described experience, reduced mental chatter, easier sleep onset, and a calmer next-day baseline, maps loosely onto what selank is actually studied for. But one good weekend is not a protocol, and her enthusiasm is running well ahead of her evidence.

Does the science back this up?

Partially, yes, but the evidence base is much thinner and more geographically narrow than TikTok enthusiasm suggests. Most of selank's clinical data comes from Russian research conducted by the Institute of Molecular Genetics in Moscow, which limits independent replication significantly.

Selank is a synthetic heptapeptide analog of tuftsin. It has been studied primarily in Russia as an anxiolytic registered under the brand Selank by Peptogen. Seredenin and Voronina (2010, Eksperimental'naya i Klinicheskaya Farmakologiya) reviewed its anxiolytic and nootropic effects, finding benzodiazepine-comparable anxiolytic activity in animal models without sedation or dependence markers. A small human trial by Zozulya et al. (2001, Bulletin of Experimental Biology and Medicine) found reduced anxiety scores in patients with generalized anxiety disorder. These are not large, multicenter, placebo-controlled trials published in Western peer-reviewed journals. They are promising, not proven.

On sleep specifically, the evidence is even thinner. Selank is not classified as a sleep aid in any jurisdiction.

What did they get wrong (or right)?

She got the general direction right: selank does appear to have anxiolytic properties in the studies that exist. Her description of reduced "overstimulation" and mental quieting is consistent with its proposed GABAergic and serotonergic modulation mechanisms. Give credit where it is due.

What she got wrong is the confidence level. Saying "this is what I'm supposed to feel like" after a single dose is the kind of conclusion that takes weeks of controlled observation, not a Friday night. The placebo effect for anxiolytics is substantial. Rief et al. (2009, Journal of Affective Disorders) documented placebo response rates of 30 to 40 percent in anxiety trials. One good night's sleep after trying something new you believe in is not signal, it is noise.

Her proposed cycling protocol, five days on, two days off, has no published basis in the selank literature. She may have borrowed this from broader peptide cycling logic, but presenting it as a plan implies more scientific grounding than exists. This is where the video slides from personal sharing into something that looks like guidance.

What should you actually know?

Selank is not FDA-approved. It is not legally available as a pharmaceutical in the United States. It exists in a gray market as a research chemical, which means quality control, purity, and dosing consistency vary significantly between suppliers. This is not a minor footnote. It is the most important thing to understand before anyone buys it based on a TikTok.

The mechanism most researchers point to involves selank's effect on GABA-A receptor modulation and its influence on brain-derived neurotrophic factor (BDNF), documented by Kozlovskaya et al. (2014, Doklady Biological Sciences). These are legitimate pharmacological targets for anxiety. But "legitimate target" and "proven safe and effective in your specific situation" are not the same sentence.

Anyone considering selank should talk to a licensed clinician who understands peptide pharmacology, not derive a protocol from a 60-second video. The absence of serious side effects in existing literature is reassuring but not exonerating, since long-term human safety data simply does not exist at scale.